Pancreatic safety of newer incretin-based therapies: Are the "-tides " finally turning?

Diabetes

Volumn 63, Issue 7, 2014, Pages 2219-2221

  Devaraj, Sridevi ^a   Maitra, Anirban ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EXENDIN 4; GLIPIZIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; INCRETIN; LIRAGLUTIDE; NATEGLINIDE; REPAGLINIDE; ROSIGLITAZONE; SITAGLIPTIN;

APOPTOSIS; CELL PROTECTION; DIABETES MELLITUS; LONG TERM CARE; MONOTHERAPY; NONHUMAN; NOTE; PANCREAS; PANCREAS ADENOCARCINOMA; PANCREAS ADENOMA; PANCREAS ISLET BETA CELL; PANCREATITIS; PRIORITY JOURNAL; SAFETY;

ANIMALS; FEMALE; GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-LIKE PEPTIDES; HUMANS; HYPOGLYCEMIC AGENTS; MALE; PANCREAS;

EID: 84903157595     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db14-0545     Document Type: Note

References (18)

1. Derosa G, Maffioli P. GLP-1 agonists exenatide and liraglutide: a review about their safety and efficacy. Curr Clin Pharmacol 2012;7:214-228
2. Deacon CF, Nauck MA, Toft-Nielsen M, Pridal L, Willms B, Holst JJ. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes 1995;44:1126-1131
3. Xu G, Stoffers DA, Habener JF, Bonner-Weir S. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 1999;48:2270-2276 (Pubitemid 30395416)
4. Gale EA. GLP-1 based agents and acute pancreatitis : drug safety falls victim to the three monkey paradigm. BMJ 2013;346:f1263
5. U.S. Department of Food and Drug Administration. Adverse Event Reporting System [Internet], 2011. Available from http://www.fda.gov/Drugs/ GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/default. htm. Accessed 31 March 2014
6. Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology 2011;141:150-156
7. Butler AE, Campbell-Thompson M, Gurlo T, Dawson DW, Atkinson M, Butler PC. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes 2013;62:2595-2604
8. Drucker DJ. Incretin action in the pancreas: potential promise, possible perils, and pathological pitfalls. Diabetes 2013;62:3316-3323
9. Engel SS, Golm GT, Lauring B. Comment on Butler et al. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes 2013;62:2595-2604 (Letter).
10. Diabetes 2013;62:E18
11. Kahn SE. Incretin therapy and islet pathology: a time for caution. Diabetes 2013;62:2178-2180
12. Nauck MA, Friedrich N. Do GLP-1-based therapies increase cancer risk? Diabetes Care 2013;36(Suppl. 2):S245-S252
13. Buse JB, Garber A, Rosenstock J, et al. Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials. J Clin Endocrinol Metab 2011;96:1695-1702
14. Nyborg NC, Mølck AM, Madsen LW, Knudsen LB. The human GLP-1 analog liraglutide and the pancreas: evidence for the absence of structural pancreatic changes in three species. Diabetes 2012;61:1243-1249
15. Gotfredsen CF, Mølck A-M, Thorup I, et al. The human GLP-1 analogs liraglutide and semaglutide: absence of histopathological effects on the pancreas in nonhuman primates. Diabetes 2014;63:2486-2497
16. Maitra A, Hruban RH. Pancreatic cancer. Annu Rev Pathol 2008;3:157-188 (Pubitemid 351488279)
17. Egan AG, Blind E, Dunder K, et al. Pancreatic safety of incretin-based drugs - FDA and EMA assessment. N Engl J Med 2014;370:794-797
18. European Medicines Agency. Assessment report for GLP-1 based therapies [Internet], July 2013. Available from http://www.ema.europa.eu/docs/en-GB/ document-library?Report/2013/08/WC500147026.pdf. Accessed 31 March 2014